Role of STK11 in ALK-positive non-small cell lung cancer

Anaplastic lymphoma kinase (ALK) inhibitors have been shown to be effective in treating patients with ALK-positive non-small cell lung cancer (NSCLC), and crizotinib, ceritinib and alectinib have been approved as clinical first-line therapeutic agents. The availability of these inhibitors has also l...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wen, Yan, Lu-Da, Yu, Zhi-Qiong, Li, Na, Yang, Yong-Hua, Wang, Meng, Chen, Yuan-Yuan, Mao, Meng-Xia, Peng, Xiao-Chun, Cai, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073580/
https://www.ncbi.nlm.nih.gov/pubmed/35527776
http://dx.doi.org/10.3892/ol.2022.13301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073580/
https://www.ncbi.nlm.nih.gov/pubmed/35527776
http://dx.doi.org/10.3892/ol.2022.13301

Ejemplares similares